ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes

GlobeNewswire2023-05-24

PRESS RELEASE ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes Lyon (France), May 23, 2023 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2337991976?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UlbcTXpd1.otCAz4FC_QkQ--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7afc4e6ec0c62824da12d71dd35a65b8","is_english":true,"pubTime":"2023-05-24 04:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2337991976","market":"us","top_or_hot":-1,"title":"ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes","media":"GlobeNewswire","content":"<div>\n<p>PRESS RELEASE\nERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes\nLyon (France), May 23, 2023 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), ...</p>\n\n<a href=\"https://finance.yahoo.com/news/erytech-announces-availability-exemption-document-200500736.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-24 04:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/erytech-announces-availability-exemption-document-200500736.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PRESS RELEASE\nERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes\nLyon (France), May 23, 2023 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), ...</p>\n\n<a href=\"https://finance.yahoo.com/news/erytech-announces-availability-exemption-document-200500736.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/erytech-announces-availability-exemption-document-200500736.html","article_id":"2337991976","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UlbcTXpd1.otCAz4FC_QkQ--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7afc4e6ec0c62824da12d71dd35a65b8"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2337991976","pubTimestamp":1684872300,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"PRESS RELEASE\nERYTECH announces the availability of the exemption document relating to the proposed ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"ERYTECH宣布与提议的Pherecydes组合相关的豁免文件的可用性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERYP":0.9},"content_text":"PRESS RELEASE\nERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes\nLyon (France), May 23, 2023 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has published the exemption document relating to the proposed combination with Pherecydes.\nThe document may be consulted on the company's website at www.erytech.com in the Shareholders Meeting section.\nAbout ERYTECH : www.erytech.com\nERYTECH is a biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.\nOn February 15 2023, ERYTECH announced its intended strategic combination with PHERECYDES to create a global player in extended phage. More detail can be found in the press release.\nERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.\nFor more information, please visit www.erytech.com\nCONTACTS\n\n\n\nERYTECHEric SoyerCFO & COO\nNewCapMathilde Bohin/Louis-Victor DelouvrierInvestor RelationsNicolas MerigeauMedia Relations\nLifeSci Advisors, LLCInvestor RelationsCorey Davis, Ph.D.\n\n\n+33 (0)4 78 74 44 38investors@erytech.com\n+33 (0)1 44 71 94 94ERYTECH@newcap.eu\n+1 (212) 915 - 2577cdavis@lifesciadvisors.com\n\n\n\n Attachment \n\n Erytech_PR_Availablity_Exemption document","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2337991976"}